Cardiovascular risk in patients with mild renal insufficiency: Implications for the use of ACE inhibitors

Presse Medicale

Volumn 34, Issue 18, 2005, Pages 1303-1308

  Mann, Johannes F E ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; LIPOPROTEIN A; RAMIPRIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL OBSERVATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; MORTALITY; NEPHROSCLEROSIS; PREDICTION; PROSPECTIVE STUDY; REVIEW; STROKE;

EID: 27544505618     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84178-8     Document Type: Short Survey

References (33)

1. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 1999; 10: 1606-15.
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-52.
3. Raine AEG, Schwarz U, Ritz E. The patient with uremia: hypertension and cardiac problems. In: Oxford Textbook of Clinical Nephrology, ed. by Davison AM et al., Oxford University Press, 1998; p. 1885-919.
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and erythropoietin. N Engl J Med 1998; 339: 584-90.
5. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-18.
6. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Intern 1996; 50: 1321-6.
7. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G et al. Lipoprotein (a) serum concentrations in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-15.
8. Fliser D, Kronenberg F, Kiestein JT. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. Am Soc Nephrol 2005 (in press)
9. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J, Chadefaux B. Sustained reduction of hyperhomocysteinemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14: 2903-6.
10. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-7.
11. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-9.
12. Tracy RE, Malcom GT, Oalmann MC, Newman WP 3rd, Guzman MA. Nephrosclerosis, glycohemoglobin, cholesterol, and smoking in subjects dying of coronary heart disease. Mod Pathol 1994; 7: 301-9.
13. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Intern 1999; 56: 2214-19.
14. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker of increased risk of stroke. Stroke 1997; 28: 557-63.
15. Weiner DE, Tighiouart H, MacLeod B, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community based studies. J Am Soc Nephrol 2004; 15: 1307-15.
16. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
17. Gerstein HC, Mann JFE, Qilong Y et al. Albuminuria and cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-6.
18. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A et al. Renal function, neurohormonal activation and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.
19. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA et al.; CATS Randomized Trial. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412-20.
20. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974-80.
21. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J et al. Risks associated with renal dysfunction in patients in the coronary care unit. JACC 2000; 36: 679-84.
22. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG et al. Prognostic value of serum creatinine and the effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group HDFP results. Hypertension 1989; 13 (5 Suppl): 180-93.
23. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-25.
24. Schillaci G, Reboldi G, Verdecchia P. High normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-91.
25. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidn Dis 1993; 21 (4 Suppl 1): 31-40.
26. Mann JFE, Gerstein HC, Pogue J, Lonn E, Yusuf S. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2002; 2: 157-62.
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
28. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
29. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-45.
30. Ruggenenti P, Perna P, Gherardi G, Gaspari F, Benini F, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-6.
31. Bakris GL, Weir MR. Angiotensin converting enzyme inhibitor-associated elevations in serum-creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.
32. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351: 1344-6.
33. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events and hosptalization. N Engl J Med 2004; 351: 1296-305.